MRI may sharpen radiation aim in esophageal cancer
NCT ID NCT07416825
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether using MRI scans can reduce differences in how doctors outline esophageal cancer tumors for radiation therapy. Twenty-three patients with advanced esophageal cancer had MRI scans in addition to standard CT and PET/CT scans. Five radiation oncologists independently drew tumor boundaries on each type of scan, and researchers measured how much their outlines varied. The goal was to see if MRI leads to more consistent tumor targeting.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If MRI improves consistency in tumor targeting, it could lead to more precise radiotherapy planning for esophageal cancer.
- What could go wrong
- This is a small, completed imaging study with only 23 patients, so results may not apply widely. It does not test treatment outcomes or patient survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
23 people
The number who actually took part.
- Started
-
Jan 2020
- Finished
-
Jun 2021
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥18 years * Locally advanced esophageal cancer (T1b-4b, N0-N+, M0) * Siewert type I or II for distal esophageal tumors * Planned preoperative or definitive chemoradiotherapy * Written informed consent for participation in the study * No contraindications for MRI Exclusion Criteria: * Implanted metallic objects with magnetic properties or electromagnetic devices without MRI compatibility confirmation * Physical or psychological conditions preventing informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Esophageal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Oncology Ljubljana
Ljubljana, 1000, Slovenia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Patient's own blood turned into surgical glue to stop deadly leaks
- Blood proteins may predict who beats esophageal cancer with chemoradiation
- New Antibody-Drug conjugate put to the test against Hard-to-Treat cancers
- Can a direct hit to tumors make immunotherapy work better?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Blood test aims to catch Cancer's return earlier